Pretransplant serum CXCL9 and CXCL10 levels fail to predict acute rejection in kidney transplant recipients receiving induction therapy

Transplantation

Volumn 91, Issue 8, 2011, Pages

  Heidt, Sebastiaan ^a   Shankar, Sushma ^a   Muthusamy, Anand S R ^a   San Segundo, David ^a   Wood, Kathryn J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MYCOPHENOLIC ACID; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LETTER; LYMPHOCYTE DEPLETION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REFERENCE VALUE; T LYMPHOCYTE ACTIVATION; URINE LEVEL;

ACUTE DISEASE; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; BIOLOGICAL MARKERS; CHEMOKINE CXCL10; CHEMOKINE CXCL9; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; PREOPERATIVE PERIOD; RECOMBINANT FUSION PROTEINS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79954616429     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318210de6b     Document Type: Letter

References (8)

1. Hauser IA, Spiegler S, Kiss E, et al. Prediction of acute renal allograft rejection by urinary monokine induced by IFN-gamma (MIG). J Am Soc Nephrol 2005; 16: 1849.
2. Hu H, Kwun J, Aizenstein BD, et al. Noninvasive detection of acute and chronic injuries in human renal transplant by elevation of multiple cytokines/chemokines in urine. Transplantation 2009; 87: 1814.
3. Rotondi M, Rosati A, Buonamano A, et al. High pretransplant serum levels of CXCL10/IP-10 are related to increased risk of renal allograft failure. Am J Transplant 2004; 4: 1466.
4. Rotondi M, Netti GS, Lazzeri E, et al. High pretransplant serum levels of CXCL9 are associated with increased risk of acute rejection and graft failure in kidney graft recipients. Transpl Int 2010; 23: 465.
5. Sampaio MS, Kadiyala A, Gill J, et al. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation. Transplantation 2009; 88: 904.
6. Trzonkowski P, Zilvetti M, Chapman S, et al. Homeostatic repopulation by CD28-CD8- T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression. Am J Transplant 2008; 8: 338.
7. Du J, Yang H, Zhang D, et al. Structural basis for the blockage of IL-2 signaling by therapeutic antibody basiliximab. J Immunol 2010; 184: 1361.
8. Rabin RL, Park MK, Liao F, et al. Chemokine receptor responses on T cells are achieved through regulation of both receptor expression and signaling. J Immunol 1999; 162: 3840.